Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (NCT05092958)
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and avelumab together may further shrink the cancer or prevent it from returning/progressing.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (275 Sites)
Showing the first 25 of 275 sites.
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Sutter Auburn Faith Hospital — Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Palo Alto Medical Foundation-Fremont — Fremont, California
- Memorial Medical Center — Modesto, California
- Palo Alto Medical Foundation-Camino Division — Mountain View, California
- Palo Alto Medical Foundation Health Care — Palo Alto, California
- Sutter Roseville Medical Center — Roseville, California
- Sutter Medical Center Sacramento — Sacramento, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- California Pacific Medical Center-Pacific Campus — San Francisco, California
- Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California
- Palo Alto Medical Foundation-Sunnyvale — Sunnyvale, California
- Sutter Solano Medical Center/Cancer Center — Vallejo, California
- Beebe South Coastal Health Campus — Millville, Delaware
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
- Beebe Health Campus — Rehoboth Beach, Delaware
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Cleveland Clinic-Weston — Weston, Florida
- Rush-Copley Medical Center — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Advanced Bladder Urothelial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.